CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients

@inproceedings{Lefort2017CXCR4IC,
  title={CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients},
  author={Sylvain Lefort and Aur{\'e}lie Thuleau and Yann Kieffer and Phil{\'e}mon Sirven and Ivan Bieche and Elisabetta Marangoni and Anne Vincent-Salomon and Fatima Mechta-Grigoriou},
  booktitle={Oncogene},
  year={2017}
}
The CXCR4 receptor and its ligand CXCL12 (also named stromal cell-derived factor 1, SDF1) have a critical role in chemotaxis and homing, key steps in cancer metastasis. Although myofibroblasts expressing CXCL12 are associated with the presence of axillary metastases in HER2 breast cancers (BC), the therapeutic interest of targeting CXCR4/CXCL12 axis in the different BC subtypes remains unclear. Here, we investigate this question by testing antitumor activity of CXCR4 inhibitors in patient… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis

Anxo Martinez-Ordoñez, Samuel Seoane, +8 authors Roman Perez-Fernandez
  • Oncogene
  • 2018
VIEW 2 EXCERPTS
CITES BACKGROUND

Clinicopathologic Significance of CXCL 12 and CXCR 4 Expressions in Patients with Colorectal Cancer

Naomi Yoshuantari, Didik Setyo Heriyanto, Susanna Hilda Hutajulu, Johan Kurnianda, Ahmad Ghozali
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 66 REFERENCES

negative breast cancer cells to cisplatin

A Müller, B Homey, +3 authors ME Buchanan
  • Oncotarget
  • 2015

as a new means of improving chemotherapy ef fi ciency in high - LC 3 B triple - negative breast cancers

T Gruosso, C Garnier, +3 authors D Bellanger
  • 2014

The impact of chemokine receptor CXCR 4 on breast cancer prognosis : a meta - analysis

Xu T-P, H Shen, Liu L-X, Shu Y-Q
  • Cancer Epidemiol
  • 2013